CBAY Cymabay Therapeutics

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC.

Company profile

Sujal Shah
Fiscal year end
Former names

CBAY stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


13 May 21
27 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 43.33M 43.33M 43.33M 43.33M 43.33M 43.33M
Cash burn (monthly) (positive/no burn) 1.12M 5.87M 4.69M 6.85M 4.21M
Cash used (since last report) n/a 4.36M 22.8M 18.22M 26.61M 16.37M
Cash remaining n/a 38.97M 20.52M 25.11M 16.71M 26.96M
Runway (months of cash) n/a 34.7 3.5 5.4 2.4 6.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 May 21 Dennis D Kim Employee Stock Option Common Stock Grant Aquire A No No 4.37 10,000 43.7K 10,000
17 May 21 Dennis D Kim Employee Stock Option Common Stock Grant Aquire A No No 4.37 390,000 1.7M 390,000
10 May 21 Lewis J Stuart Employee Stock Option Common Stock Grant Aquire A No No 3.94 360,000 1.42M 360,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

84.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 129 147 -12.2%
Opened positions 16 47 -66.0%
Closed positions 34 20 +70.0%
Increased positions 45 41 +9.8%
Reduced positions 35 36 -2.8%
13F shares
Current Prev Q Change
Total value 399.81M 2.77B -85.6%
Total shares 58.46M 59.41M -1.6%
Total puts 710.3K 661.4K +7.4%
Total calls 241.2K 307.3K -21.5%
Total put/call ratio 2.9 2.2 +36.8%
Largest owners
Shares Value Change
Avoro Capital Advisors 10.3M $46.76M 0.0%
BLK Blackrock 5.96M $27.05M +10.6%
Boxer Capital 4M $18.16M 0.0%
Vanguard 3.69M $16.77M +7.8%
Commodore Capital 2.98M $13.55M +100.8%
Baker Bros. Advisors 2.17M $9.85M -25.0%
Millennium Management 2.05M $9.32M +52.6%
Foresite Capital Fund III 1.79M $10.26M 0.0%
Foresite Capital Management IV 1.79M $8.11M 0.0%
Foresite Capital Management III 1.64M $7.45M 0.0%
Largest transactions
Shares Bought/sold Change
Commodore Capital 2.98M +1.5M +100.8%
Citadel Advisors 1.58M -942.45K -37.3%
GS Goldman Sachs 92.77K -848.21K -90.1%
Baker Bros. Advisors 2.17M -722.81K -25.0%
Millennium Management 2.05M +707.73K +52.6%
Vivo Capital 0 -585.39K EXIT
BLK Blackrock 5.96M +572.24K +10.6%
STT State Street 1.29M -517.5K -28.6%
Renaissance Technologies 890.16K +480.44K +117.3%
DB Deutsche Bank AG - Registered Shares 520.24K +469.59K +927.1%
Content analysis
H.S. freshman Good
New words: acquireor, AdventHealth, Biden, bilirubin, bioactive, carefully, Charitable, complaint, complementary, complimentary, constitutionality, destroying, diary, disseminating, District, Education, elafibranor, Florida, foz, fromour, Genfit, glucagon, Harry, Helmsley, hormone, hypoglycemia, imply, importantly, interface, led, Leona, meaningful, moderate, month, necessity, Northern, numerical, open, oral, Orlando, payer, proven, quarantine, Reconciliation, Reply, Restraining, stable, startup, stimulate, supranational, Supreme, temporary, thatthe, thebalance, therapeutic, thereto, tranche, Translational, Trust, understand, understanding, unspecified, upper, vigorously, warranted
Removed: acceleration, adapting, Aid, AMT, analog, announcement, applied, assured, ASU, Blueprint, borrow, borrowing, Breakthrough, canceled, capitalized, capitalizing, carryback, cholestatic, cholesterol, closed, cloud, collateralized, COMP, component, composite, computing, contracted, Cumulatively, customer, deductibility, deducting, designation, determined, diffuse, director, disclosing, discount, dissolution, endpoint, entirety, environment, escalate, estimated, estimating, exacerbated, exclude, exercise, exercised, experiencing, extend, extrahepatic, feet, FFCR, fixed, fourth, globally, hosting, implicit, improved, incentivize, incremental, incurrence, Interaction, intrahepatic, itching, Johnson, lease, leased, lessor, liberalizing, limitation, lipoprotein, list, longer, Low, median, Medicinal, minimum, modifying, negotiating, NOL, noncancelable, nonemployee, nonrefundable, offering, optional, orphan, parallel, participant, pertaining, placement, pocket, power, presently, pressure, PRIME, PRIority, proportionate, prospectively, provision, PSC, rare, ratably, realignment, realizability, recognize, refundable, released, remaining, remeasurement, removed, removing, reorganization, resource, retrospectively, revise, sclerosing, secondary, separate, September, shareholder, shelf, shut, sick, space, square, stemming, sublicense, subsidiary, substantiated, suggest, summarize, sustained, symptom, taxable, temporarily, today, tolerability, treated, UDCA, ULN, underlying, underwriting, underwritten, undisclosed, utilization, utilized, variable, VAS, vest, vested, visual, week, withdrawn, worsening